The role of new technologies in myeloproliferative neoplasms

Giuseppe A. Palumbo, Stefania Stella, Maria Stella Pennisi, Cristina Pirosa, Elisa Fermo, Sonia Fabris, Daniele Cattaneo, Alessandra Iurlo

Research output: Contribution to journalReview article

Abstract

The hallmark of BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in JAK2, CALR, or MPL gene. These genetic alterations represent a key feature, useful for diagnostic, prognostic and therapeutical approaches. Molecular biology tests are now widely available with different specificity and sensitivity. Recently, the allele burden quantification of driver mutations has become a useful tool, both for prognostication and efficacy evaluation of therapies. Moreover, other sub-clonal mutations have been reported in MPN patients, which are associated with poorer prognosis. ASXL1 mutation appears to be the worst amongst them. Both driver and sub-clonal mutations are now taken into consideration in new prognostic scoring systems and may be better investigated using next generation sequence (NGS) technology. In this review we summarize the value of NGS and its contribution in providing a comprehensive picture of mutational landscape to guide treatment decisions. Finally, discussing the role that NGS has in defining the potential risk of disease development, we forecast NGS as the standard molecular biology technique for evaluating these patients.

Original languageEnglish
Article number321
JournalFrontiers in Oncology
Volume9
Issue numberAPR
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Technology
Mutation
Neoplasms
Molecular Biology
Alleles
Sensitivity and Specificity
Therapeutics
Genes

Keywords

  • ASXL1 mutation
  • BCR-ABL1-negative myeloproliferative neoplasms (MPNs)
  • Calreticulin (CALR)
  • High molecular risk (HMR) mutations
  • JAK2 mutations
  • MPL (W515K/L)
  • Myelofibrosis (MF)
  • Next generation sequencing (NGS)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The role of new technologies in myeloproliferative neoplasms. / Palumbo, Giuseppe A.; Stella, Stefania; Pennisi, Maria Stella; Pirosa, Cristina; Fermo, Elisa; Fabris, Sonia; Cattaneo, Daniele; Iurlo, Alessandra.

In: Frontiers in Oncology, Vol. 9, No. APR, 321, 01.01.2019.

Research output: Contribution to journalReview article

Palumbo, Giuseppe A. ; Stella, Stefania ; Pennisi, Maria Stella ; Pirosa, Cristina ; Fermo, Elisa ; Fabris, Sonia ; Cattaneo, Daniele ; Iurlo, Alessandra. / The role of new technologies in myeloproliferative neoplasms. In: Frontiers in Oncology. 2019 ; Vol. 9, No. APR.
@article{08bed5c477724c86968457d2c6270e0e,
title = "The role of new technologies in myeloproliferative neoplasms",
abstract = "The hallmark of BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in JAK2, CALR, or MPL gene. These genetic alterations represent a key feature, useful for diagnostic, prognostic and therapeutical approaches. Molecular biology tests are now widely available with different specificity and sensitivity. Recently, the allele burden quantification of driver mutations has become a useful tool, both for prognostication and efficacy evaluation of therapies. Moreover, other sub-clonal mutations have been reported in MPN patients, which are associated with poorer prognosis. ASXL1 mutation appears to be the worst amongst them. Both driver and sub-clonal mutations are now taken into consideration in new prognostic scoring systems and may be better investigated using next generation sequence (NGS) technology. In this review we summarize the value of NGS and its contribution in providing a comprehensive picture of mutational landscape to guide treatment decisions. Finally, discussing the role that NGS has in defining the potential risk of disease development, we forecast NGS as the standard molecular biology technique for evaluating these patients.",
keywords = "ASXL1 mutation, BCR-ABL1-negative myeloproliferative neoplasms (MPNs), Calreticulin (CALR), High molecular risk (HMR) mutations, JAK2 mutations, MPL (W515K/L), Myelofibrosis (MF), Next generation sequencing (NGS)",
author = "Palumbo, {Giuseppe A.} and Stefania Stella and Pennisi, {Maria Stella} and Cristina Pirosa and Elisa Fermo and Sonia Fabris and Daniele Cattaneo and Alessandra Iurlo",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2019.00321",
language = "English",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - The role of new technologies in myeloproliferative neoplasms

AU - Palumbo, Giuseppe A.

AU - Stella, Stefania

AU - Pennisi, Maria Stella

AU - Pirosa, Cristina

AU - Fermo, Elisa

AU - Fabris, Sonia

AU - Cattaneo, Daniele

AU - Iurlo, Alessandra

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The hallmark of BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in JAK2, CALR, or MPL gene. These genetic alterations represent a key feature, useful for diagnostic, prognostic and therapeutical approaches. Molecular biology tests are now widely available with different specificity and sensitivity. Recently, the allele burden quantification of driver mutations has become a useful tool, both for prognostication and efficacy evaluation of therapies. Moreover, other sub-clonal mutations have been reported in MPN patients, which are associated with poorer prognosis. ASXL1 mutation appears to be the worst amongst them. Both driver and sub-clonal mutations are now taken into consideration in new prognostic scoring systems and may be better investigated using next generation sequence (NGS) technology. In this review we summarize the value of NGS and its contribution in providing a comprehensive picture of mutational landscape to guide treatment decisions. Finally, discussing the role that NGS has in defining the potential risk of disease development, we forecast NGS as the standard molecular biology technique for evaluating these patients.

AB - The hallmark of BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in JAK2, CALR, or MPL gene. These genetic alterations represent a key feature, useful for diagnostic, prognostic and therapeutical approaches. Molecular biology tests are now widely available with different specificity and sensitivity. Recently, the allele burden quantification of driver mutations has become a useful tool, both for prognostication and efficacy evaluation of therapies. Moreover, other sub-clonal mutations have been reported in MPN patients, which are associated with poorer prognosis. ASXL1 mutation appears to be the worst amongst them. Both driver and sub-clonal mutations are now taken into consideration in new prognostic scoring systems and may be better investigated using next generation sequence (NGS) technology. In this review we summarize the value of NGS and its contribution in providing a comprehensive picture of mutational landscape to guide treatment decisions. Finally, discussing the role that NGS has in defining the potential risk of disease development, we forecast NGS as the standard molecular biology technique for evaluating these patients.

KW - ASXL1 mutation

KW - BCR-ABL1-negative myeloproliferative neoplasms (MPNs)

KW - Calreticulin (CALR)

KW - High molecular risk (HMR) mutations

KW - JAK2 mutations

KW - MPL (W515K/L)

KW - Myelofibrosis (MF)

KW - Next generation sequencing (NGS)

UR - http://www.scopus.com/inward/record.url?scp=85067435355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067435355&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00321

DO - 10.3389/fonc.2019.00321

M3 - Review article

AN - SCOPUS:85067435355

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - APR

M1 - 321

ER -